Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma Inc (NASDAQ: CUE) is a clinical-stage biopharmaceutical company pioneering targeted immunotherapies through its innovative Immuno-STAT platform. This page serves as the definitive source for official company announcements, research developments, and strategic updates.
Investors and industry observers will find curated press releases covering clinical trial progress, regulatory milestones, and partnership announcements. Our collection includes updates on CUE-100 series candidates for oncology applications and autoimmune disease programs, along with financial reporting and executive commentary.
All content is sourced directly from company filings and authorized communications, ensuring reliability for those monitoring advancements in T cell-modulating therapies. Key focus areas include phase 1/2 trial results, platform technology enhancements, and collaboration updates with leading research institutions.
Bookmark this page for streamlined access to Cue Biopharma's latest scientific achievements and corporate developments in the competitive immunotherapy landscape. Check regularly for real-time updates on this innovative biologics developer.
Cue Biopharma (Nasdaq: CUE) has announced the pricing of a public offering expected to raise approximately $20 million in gross proceeds. The offering includes:
- 13,530,780 shares of common stock with warrants to purchase 3,382,695 additional shares
- Pre-funded warrants to purchase 11,469,216 shares with warrants to purchase 2,867,304 additional shares
The common stock and accompanying warrants are priced at $0.79 per combined unit, while pre-funded warrants and accompanying warrants are priced at $0.789. Common stock warrants have a 5-year term with an exercise price of $0.79, while pre-funded warrants have a $0.001 exercise price. The offering is expected to close around April 16, 2025, with Oppenheimer & Co. Inc. acting as sole book-running manager.
Cue Biopharma (Nasdaq: CUE), a clinical-stage biopharmaceutical company, has announced plans for an underwritten public offering of common stock shares and accompanying warrants. The company, which develops therapeutic biologics for cancer and autoimmune disease treatment, will also offer pre-funded warrants to purchase common stock as an alternative.
The offering will be managed by Oppenheimer & Co. Inc. as the sole book-running manager, with Newbridge Securities serving as co-manager. The offering's completion, size, and terms are subject to market conditions and cannot be guaranteed.
The securities will be offered under a shelf registration statement on Form S-3 (File No. 333-271786) that was filed with the SEC on May 9, 2023, and became effective on May 26, 2023. A preliminary prospectus supplement will be filed with the SEC.
Cue Biopharma (Nasdaq: CUE), a clinical-stage biopharmaceutical company, has announced a business update conference call and webcast scheduled for Tuesday, April 15, 2025, at 4:30 p.m. ET. The company, which focuses on developing therapeutic biologics for cancer and autoimmune disease treatment through selective T cell engagement and modulation, will make the presentation available to investors through multiple channels.
Access details include:
- Domestic investors: 1-844-826-3035
- International investors: 1-412-317-5195
- Conference ID: 10199037
Cue Biopharma (Nasdaq: CUE) and Boehringer Ingelheim have announced a strategic research collaboration and license agreement to develop CUE-501, a novel B cell depletion therapy for autoimmune diseases. The partnership focuses on developing a first-in-class bispecific compound that targets specific B cells through T cell mediated depletion.
The preclinical candidate molecule works by binding to B cell specific membrane proteins while engaging virus-specific memory killer T cells, potentially offering improved benefits and safety compared to existing B cell targeting approaches. Under the agreement terms, Cue Biopharma will receive:
- $12 million upfront payment plus research support
- Up to $345 million in potential milestone payments
- Royalty payments on net sales
This collaboration aims to expand Boehringer's autoimmune and inflammatory disease pipeline, targeting earlier treatment intervention and long-term disease control.
Cue Biopharma (Nasdaq: CUE) reported its Q4 and full year 2024 financial results. The company's collaboration revenue for Q4 2024 was $1.6 million, down from $1.8 million in Q4 2023. Full-year collaboration revenue increased to $9.3 million from $5.5 million in 2023, driven by the Ono Pharmaceutical partnership.
R&D expenses decreased to $7.2 million in Q4 2024 from $10.9 million in Q4 2023, while G&A expenses reduced to $4.0 million from $4.6 million. For the full year, R&D expenses were $36.3 million (down from $40.8 million) and G&A expenses were $14.6 million (down from $16.7 million).
The company appointed new leadership including Lucinda Warren as Chief Business Officer and Daniel Baker as Interim Chief Development Officer. Cue regained worldwide rights for CUE-401, their lead autoimmune program, and advanced CUE-501 development. Cash position stood at $22.5 million as of December 31, 2024.
Cue Biopharma (Nasdaq: CUE) has granted an inducement option award to its newly appointed interim chief development officer, Daniel Baker, M.D. The award consists of options to purchase 200,000 shares of company common stock at $1.06 per share, based on the closing price on November 25, 2024. The options will vest over two years in four equal installments, starting six months from the grant date, contingent on continued employment.
Cue Biopharma (Nasdaq: CUE), a clinical-stage biopharmaceutical company, announced its participation in a fireside discussion at the Piper Sandler 36th Annual Healthcare Conference in New York, NY, from December 3-5, 2024. The company will present updates on clinical and preclinical programs, along with strategic business and partnering objectives.
The presentation will be delivered by CEO Daniel Passeri on Wednesday, December 4, 2024, from 9:00 AM to 9:25 AM EST. A live webcast will be available, and the recording will be archived for 30 days on the company's website.
Cue Biopharma reported Q3 2024 financial results and clinical progress. The company's Phase 1 trial of CUE-101 with KEYTRUDA showed 46% objective response rate and 91.3% 12-month survival in HPV+ head and neck cancer patients. CUE-102 demonstrated 67% disease control rate in pancreatic cancer. Financially, collaboration revenue increased to $3.3M from $2.1M year-over-year, while R&D expenses decreased to $9.4M from $9.9M. The company ended Q3 with $32.4M in cash, expected to fund operations into Q4 2025.
Cue Biopharma (Nasdaq: CUE) announced key organizational changes with Daniel Baker, M.D., joining as interim chief development officer (CDO) effective November 25, 2024. Dr. Anish Suri will transition from president & chief scientific officer to principal research and immunology advisor. Dr. Baker brings over 20 years of pharmaceutical industry experience, notably serving as Vice President of Immunology R&D at Johnson & Johnson, where he oversaw multiple successful drug developments leading to 15+ regulatory approvals. The transition aims to enhance the company's pipeline development in oncology and autoimmunity.
Cue Biopharma (Nasdaq: CUE) announced its participation in a fireside chat at the Stifel 2024 Healthcare Conference in New York, scheduled for November 18-19, 2024. The company will present updates on its oncology and autoimmune disease programs, including recent data from Phase 1 clinical trials of CUE-101 and CUE-102 previously presented at SITC 2024.
CEO Daniel Passeri will lead the presentation on Tuesday, November 19, from 1:15-1:45 p.m. EST. The fireside chat will be accessible via webcast and archived for 30 days on the company's website.
